Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Barth Dominik Andreas |

** = Publikationen gelistet in SCI/SSCI/Pubmed

2022

Originalarbeit (Zeitschrift)

** Barth, DA; Stanzer, S; Spiegelberg, J; Bauernhofer, T; Absenger, G; Posch, F; Lipp, R; Halm, M; Szkandera, J; Balic, M; Gerger, A; Smolle, MA; Hutterer, GC; Klec, C; Jost, PJ; Kargl, J; Stradner, M; Pichler, M Evaluation of autoantibodies as predictors of treatment response and immune-related adverse events during the treatment with immune checkpoint inhibitors: A prospective longitudinal pan-cancer study.
Cancer Med. 2022; 11(16):3074-3083 Doi: 10.1002/cam4.4675 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Barth, DA; Stanzer, S; Spiegelberg, JA; Bauernhofer, T; Absenger, G; Szkandera, J; Gerger, A; Smolle, MA; Hutterer, GC; Ahyai, SA; Madl, T; Posch, F; Riedl, JM; Klec, C; Jost, PJ; Kargl, J; Stradner, MH; Pichler, M Patterns of Peripheral Blood B-Cell Subtypes Are Associated With Treatment Response in Patients Treated With Immune Checkpoint Inhibitors: A Prospective Longitudinal Pan-Cancer Study.
Front Immunol. 2022; 13: 840207 Doi: 10.3389/fimmu.2022.840207 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Fluhrer, H; Hutterer, GC; Golbeck, S; Stidl, M; Niedrist, T; Pichler, R; Mischinger, J; Seles, M; Mannweiler, S; Spiegelberg, J; Bauernhofer, T; Jost, PJ; Ahyai, S; Zigeuner, R; Pichler, M; Barth, DA Improved overall survival of metastatic renal cell carcinoma patients in the era of modern tyrosine kinase inhibitors and immune checkpoint inhibitors: results from a real-life, population-based Austrian study comprising three decades of follow-up.
Ther Adv Med Oncol. 2022; 14: 17588359221134065 Doi: 10.1177/17588359221134065 [OPEN ACCESS]
PubMed PUBMED Central FullText FullText_MUG

 

** Juracek, J; Madrzyk, M; Stanik, M; Ruckova, M; Trachtova, K; Malcikova, H; Lzicarova, E; Barth, DA; Pichler, M; Slaby, O A tissue miRNA expression pattern is associated with disease aggressiveness of localized prostate cancer
PROSTATE. 2022; Doi: 10.1002/pros.24466
Web of Science PubMed FullText FullText_MUG

 

** Maisel, F; Smolle, MA; Mollnar, S; Riedl, JM; Barth, DA; Seles, M; Terbuch, A; Rossmann, CH; Eisner, F; Mannweiler, S; Hutterer, G; Zigeuner, R; Pummer, K; Smolle-Jüttner, FM; Lindenmann, J; Stotz, M; Gerger, A; Jost, PJ; Bauernhofer, T; Pichler, M; Posch, F Benefit of Metastasectomy in Renal Cell Carcinoma: A Propensity Score Analysis.
Clin Genitourin Cancer. 2022; 20(4):344-353 Doi: 10.1016/j.clgc.2022.03.010
Web of Science PubMed FullText FullText_MUG

 

** Prinz, F; Jonas, K; Balihodzic, A; Klec, C; Reicher, A; Barth, DA; Riedl, J; Gerger, A; Kiesslich, T; Mayr, C; Rinner, B; Kargl, J; Pichler, M MicroRNA mimics can distort physiological microRNA effects on immune checkpoints by triggering an antiviral interferon response.
RNA Biol. 2022; 19(1):1305-1315 Doi: 10.1080/15476286.2022.2152978 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Riedl, JM; Schwarzenbacher, E; Moik, F; Horvath, L; Gantschnigg, A; Renneberg, F; Posch, F; Barth, DA; Stotz, M; Pichler, M; Hatzl, S; Fandler-Höfler, S; Gressenberger, P; Gary, T; Jost, PJ; Greil, R; Ay, C; Djanani, A; Gerger, A; Schlick, K Patterns of Thromboembolism in Patients with Advanced Pancreatic Cancer Undergoing First-Line Chemotherapy with FOLFIRINOX or Gemcitabine/nab-Paclitaxel.
Thromb Haemost. 2022; 122(4):633-645 Doi: 10.1055/a-1548-4847
Web of Science PubMed FullText FullText_MUG

 

** Smolle, MA; Helmberg, W; Matzhold, EM; Barth, DA; Sareban, N; Szkandera, J; Liegl-Atzwanger, B; Leithner, A; Pichler, M Impact of allogeneic red blood cell transfusion on prognosis in soft tissue sarcoma patients. A single-centre study.
Cancer Med. 2022; Doi: 10.1002/cam4.4989
Web of Science PubMed FullText FullText_MUG

 

Abstract (Zeitschrift)

** Riedl, JM; Barth, D; Steinlechner, S; Moik, F; Posch, F; Schlintl, V; Mayer, MC; Sandner, AM; Berton, F; Koch, L; John, N; Wurm, R; Pichler, M; Absenger, G; Jost, PJ; Wohlkonig, C; Richtig, E; Winder, T; Gerger, A; Terbuch, A Early CRP Kinetics after Initiation of Immune Checkpoint Inhibitors is a predictive Biomarker for Treatment Response independent of the Tumor Antity
ONCOL RES TREAT. 2022; 45(SUPPL 2):228-228.-Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie; Okt 7-10, 2022; Wien. [Poster]
Web of Science

 

2021

Originalarbeit (Zeitschrift)

** Barth, DA; Sareban, N; Lindner, AK; Daller, LAJ; Matzhold, EM; Hutterer, G; Smolle, M; Mischinger, J; Riedl, JM; Seles, M; Mannweiler, S; Bauernhofer, T; Pummer, K; Pichler, R; Zigeuner, R; Schlenke, P; Pichler, M Prognostic relevance of ABO blood group system in non-metastatic renal cell carcinoma: An analysis of two independent European cohorts with long-term follow-up.
Urol Oncol. 2021; 39(10):736.e9-736.e16 Doi: 10.1016/j.urolonc.2021.06.005 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

** Müller, M; Posch, F; Kiem, D; Barth, D; Horvath, L; Stotz, M; Schaberl-Moser, R; Pichler, M; Greil, R; Jost, PJ; Seeber, A; Amann, A; Schlick, K; Gerger, A; Riedl, JM Benefit of second-line therapy for advanced esophageal squamous cell carcinoma: a tri-center propensity score analysis.
Ther Adv Med Oncol. 2021; 13: 17588359211039930 Doi: 10.1177/17588359211039930 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Posch, F; Prinz, F; Balihodzic, A; Mayr, C; Kiesslich, T; Klec, C; Jonas, K; Barth, DA; Riedl, JM; Gerger, A; Pichler, M MiR-200c-3p Modulates Cisplatin Resistance in Biliary Tract Cancer by ZEB1-Independent Mechanisms.
Cancers (Basel). 2021; 13(16): Doi: 10.3390/cancers13163996 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Riedl, JM; Posch, F; Horvath, L; Gantschnigg, A; Renneberg, F; Schwarzenbacher, E; Moik, F; Barth, DA; Rossmann, CH; Stotz, M; Schaberl-Moser, R; Pichler, M; Stöger, H; Greil, R; Djanani, A; Schlick, K; Gerger, A Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis.
Eur J Cancer. 2021; 151: 3-13. Doi: 10.1016/j.ejca.2021.03.040 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

** Scheipner, L; Smolle, MA; Barth, D; Posch, F; Stotz, M; Pichler, M; StÖger, H; Gerger, A; Riedl, JM The AST/ALT Ratio Is an Independent Prognostic Marker for Disease-free Survival in Stage II and III Colorectal Carcinoma.
Anticancer Res. 2021; 41(1):429-436 Doi: 10.21873/anticanres.14792
Web of Science PubMed FullText FullText_MUG

 

Übersichtsarbeit

** Balihodzic, A; Barth, DA; Prinz, F; Pichler, M Involvement of Long Non-Coding RNAs in Glucose Metabolism in Cancer.
Cancers (Basel). 2021; 13(5): 977 Doi: 10.3390/cancers13050977 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Taheri, M; Barth, DA; Kargl, J; Rezaei, O; Ghafouri-Fard, S; Pichler, M Emerging Role of Non-Coding RNAs in Regulation of T-Lymphocyte Function.
Front Immunol. 2021; 12: 756042 Doi: 10.3389/fimmu.2021.756042 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

2020

Originalarbeit (Zeitschrift)

** Barth, DA; Brenner, C; Riedl, JM; Prinz, F; Klocker, EV; Schlick, K; Kornprat, P; Lackner, K; Stöger, H; Stotz, M; Gerger, A; Pichler, M External validation of the prognostic relevance of the advanced lung cancer inflammation index (ALI) in pancreatic cancer patients.
Cancer Med. 2020; 9(15):5473-5479 Doi: 10.1002/cam4.3233 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Klocker, EV; Barth, DA; Riedl, JM; Prinz, F; Szkandera, J; Schlick, K; Kornprat, P; Lackner, K; Lindenmann, J; Stöger, H; Stotz, M; Gerger, A; Pichler, M Decreased Activity of Circulating Butyrylcholinesterase in Blood Is an Independent Prognostic Marker in Pancreatic Cancer Patients.
Cancers (Basel). 2020; 12(5): Doi: 10.3390/cancers12051154 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Riedl, JM; Barth, DA; Brueckl, WM; Zeitler, G; Foris, V; Mollnar, S; Stotz, M; Rossmann, CH; Terbuch, A; Balic, M; Niedrist, T; Bertsch, T; Stoeger, H; Pichler, M; Olschewski, H; Absenger, G; Ficker, JH; Gerger, A; Posch, F C-Reactive Protein (CRP) Levels in Immune Checkpoint Inhibitor Response and Progression in Advanced Non-Small Cell Lung Cancer: A Bi-Center Study.
Cancers (Basel). 2020; 12(8): Doi: 10.3390/cancers12082319 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Seles, M; Hutterer, GC; Foßelteder, J; Svoboda, M; Resel, M; Barth, DA; Pichler, R; Bauernhofer, T; Zigeuner, RE; Pummer, K; Slaby, O; Klec, C; Pichler, M Long Non-Coding RNA PANTR1 is Associated with Poor Prognosis and Influences Angiogenesis and Apoptosis in Clear-Cell Renal Cell Cancer.
Cancers (Basel). 2020; 12(5): 1200 Doi: 10.3390/cancers12051200 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Stotz, M; Barth, DA; Riedl, JM; Asamer, E; Klocker, EV; Kornprat, P; Hutterer, GC; Prinz, F; Lackner, K; Stöger, H; Gerger, A; Pichler, M The Lipase/Amylase Ratio (LAR) in Peripheral Blood Might Represent a Novel Prognostic Marker in Patients with Surgically Resectable Pancreatic Cancer.
Cancers (Basel). 2020; 12(7): Doi: 10.3390/cancers12071798 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Übersichtsarbeit

** Barth, DA; Drula, R; Ott, L; Fabris, L; Slaby, O; Calin, GA; Pichler, M Circulating Non-coding RNAs in Renal Cell Carcinoma-Pathogenesis and Potential Implications as Clinical Biomarkers.
Front Cell Dev Biol. 2020; 8:828 Doi: 10.3389/fcell.2020.00828 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Barth, DA; Juracek, J; Slaby, O; Pichler, M; Calin, GA lncRNA and Mechanisms of Drug Resistance in Cancers of the Genitourinary System.
Cancers (Basel). 2020; 12(8): Doi: 10.3390/cancers12082148 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Barth, DA; Prinz, F; Teppan, J; Jonas, K; Klec, C; Pichler, M Long-Noncoding RNA (lncRNA) in the Regulation of Hypoxia-Inducible Factor (HIF) in Cancer.
Noncoding RNA. 2020; 6(3): Doi: 10.3390/ncrna6030027 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Henzinger, H; Barth, DA; Klec, C; Pichler, M Non-Coding RNAs and SARS-Related Coronaviruses.
Viruses. 2020; 12(12): Doi: 10.3390/v12121374 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Teppan, J; Barth, DA; Prinz, F; Jonas, K; Pichler, M; Klec, C Involvement of Long Non-Coding RNAs (lncRNAs) in Tumor Angiogenesis.
Noncoding RNA. 2020; 6(4): Doi: 10.3390/ncrna6040042 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Fallbericht

** Lembeck, AL; Puchas, P; Hutterer, G; Barth, DA; Terbuch, A; Bauernhofer, T; Pichler, M MicroRNAs as Appropriate Discriminators in Non-Specific Alpha-Fetoprotein (AFP) Elevation in Testicular Germ Cell Tumor Patients.
Noncoding RNA. 2020; 6(1): Doi: 10.3390/ncrna6010002 (- Case Report) [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Abstract (Zeitschrift)

** Posch, F; Barth, D; Brueckl, WM; Zeitler, G; Foris, V; Mollnar, S; Stotz, M; Rossmann, CH; Terbuch, A; Balic, M; Niedrist, T; Bertsch, T; Stoger, H; Pichler, M; Olschewski, H; Absenger, G; Ficker, JH; Gerger, A; Riedl, JM C-reactive protein (CRP) levels in immune checkpoint inhibitor response and progression in advanced non-small cell lung cancer: A bi-center study.
ANN ONCOL. 2020; 31: S286-S286.-ESMO Virtual Congress; SEP 19-OCT 18, 2020; ELECTR NETWORK. Doi: 10.1016/j.annonc.2020.08.234 [Poster] [OPEN ACCESS]
Web of Science FullText FullText_MUG

 

** Riedl, J; Posch, F; Horvath, L; Gantschnigg, A; Renneberg, F; Schwarzenbacher, E; Moik, F; Barth, D; Schaberl-Moser, R; Stotz, M; Pichler, M; Stoger, H; Greil, R; Djanani, A; Schlick, K; Gerger, A FOLFIRINOX versus Gemcitabine/nab-Paclitaxel as palliative first-line treatment of advanced pancreatic cancer: An Austrian observational Tri-Center comparative effectiveness analysis.
ONCOL RES TREAT. 2020; 43(SUPPL 4):215-215. [Poster]
Web of Science

 

** Riedl, JM; Posch, F; Gantschnigg, A; Horvath, L; Renneberg, F; Schwarzenbacher, E; Moik, F; Barth, D; Stotz, M; Schaberl-Moser, R; Pichler, M; Stoger, H; Greil, R; Djanani, A; Schlick, K; Gerger, A FOLFIRINOX versus Gemcitabine/nabPaclitaxel as First-line palliative Therapy in advanced Pancreatic Cancer: a Propensity-Score Analysis.
WIEN KLIN WOCHENSCHR. Abstracts 51. Jahrestagung der Österreichischen Gesellschaft für Innere Medizin. 2020; 132(SUPPL 2):78-79.-51. Jahrestagung der Österreichischen Gesellschaft für Innere Medizin; SEP 24-26, 2020; Salzburg, AUSTRIA. [Poster]
Web of Science

 

** Riedl, JM; Posch, F; Horvath, L; Gantschnigg, A; Renneberg, F; Schwarzenbacher, E; Moik, F; Barth, D; Stotz, M; Schaberl-Moser, R; Pichler, M; Stoger, H; Greil, R; Djanani, A; Schlick, K; Gerger, A Gemcitabine/nab-paclitaxel versus (modified) FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis.
ANN ONCOL. 2020; 31: S942-S942.-ESMO Virtual Congress; SEP 19-OCT 18, 2020; ELECTR NETWORK. Doi: 10.1016/j.annonc.2020.08.2013 [Poster] [OPEN ACCESS]
Web of Science FullText FullText_MUG

 

** Schwarzenbacher, E; Moik, F; Horvath, L; Renneberg, F; Posch, F; Barth, D; Gantschnigg, A; Schaberl-Moser, R; Pichler, M; Stotz, M; Stoger, H; Ay, C; Greil, R; Gerger, A; Djanani, A; Schlick, K; Riedl, J Incidence, prediction and outcome of venous and arterial thromboembolism in patients with advanced pancreatic cancer treated with palliative first line chemotherapy of Gemcitabine/nab-Paclitxel or FOLFIRINOX.
ONCOL RES TREAT. 2020; 43(SUPPL 4):214-214. [Poster]
Web of Science

 

** Schwarzenbacher, E; Moik, F; Posch, F; Horvath, L; Gantschnigg, A; Renneberg, F; Barth, D; Stotz, M; Schaberl-Moser, R; Pichler, M; Ay, C; Stoger, H; Greil, R; Djanani, A; Gerger, A; Schlick, K; Riedl, JM Patterns of venous and arterial thromboembolism in patients with advanced pancreatic cancer treated with palliative first line chemotherapy of gemcitabine/nab-paclitxel or FOLFIRINOX.
ANN ONCOL. 2020; 31: S949-S950.-ESMO Virtual Congress; SEP 19-OCT 18, 2020; ELECTR NETWORK. Doi: 10.1016/j.annonc.2020.08.2035 [Poster] [OPEN ACCESS]
Web of Science FullText FullText_MUG

 

2019

Originalarbeit (Zeitschrift)

** Barth, DA; Riedl, JM; Posch, F; Smolle, MA; Kasparek, AK; Niedrist, T; Szkandera, J; Stöger, H; Pichler, M; Stotz, M; Gerger, A Critical evaluation of platelet size as a prognostic biomarker in colorectal cancer across multiple treatment settings: a retrospective cohort study.
Clin Transl Oncol. 2019; 21(8):1034-1043 Doi: 10.1007/s12094-019-02037-7 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Übersichtsarbeit

** Barth, DA; Slaby, O; Klec, C; Juracek, J; Drula, R; Calin, GA; Pichler, M Current Concepts of Non-Coding RNAs in the Pathogenesis of Non-Clear Cell Renal Cell Carcinoma.
Cancers (Basel). 2019; 11(10): Doi: 10.3390/cancers11101580 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Abstract (Zeitschrift)

** Barth, DA; Riedl, JM; Foris, V; Posch, F; Mollnar, S; Stotz, M; Pichler, M; Stoger, H; Absenger, G; Olschewski, H; Gerger, A External validation and longitudinal extension of the LIPI (lung immune prognostic index) for immunotherapy outcomes in advanced non-small cell lung cancer
ONCOL RES TREAT. 2019; 42: 108-108. [Poster]
Web of Science

 

** Riedl, JM; Barth, D; Posch, F; Foris, V; Absenger, G; Mollnar, S; Pichler, M; Stotz, M; Stoger, H; Olschewski, H; Gerger, A Longitudinal C-reactive protein (CRP) trajectories predict immune checkpoint inhibitor response and progression in advanced non-small cell lung cancer
ONCOL RES TREAT. 2019; 42: 115-115. [Poster]
Web of Science

 

** Riedl, JM; Barth, DA; Foris, V; Posch, F; Mollnar, S; Stotz, M; Pichler, M; Stoger, H; Absenger, G; Olschewski, H; Gerger, A External validation and longitudinal extension of the LIPI (Lung Immune Prognostic Index) for immunotherapy outcomes in advanced non-small cell lung cancer
ANN ONCOL. 2019; 30: -44th Congress of the European-Society-for-Medical-Oncology (ESMO); SEP 27-OCT 01, 2019; Barcelona, SPAIN. [Poster]
Web of Science

 

© Med Uni Graz Impressum